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Abstract
Background: Matrix metalloproteinases (MMPs) are involved in remodeling of the extracellular matrix (ECM) during
pregnancy and parturition. Aberrant ECM degradation by MMPs or an imbalance between MMPs and their tissue inhibitors
(TIMPs) have been implicated in the pathogenesis of preterm labor, however few studies have investigated MMPs or TIMPs
in maternal serum. Therefore, the purpose of this study was to determine serum concentrations of MMP-3, MMP-9 and all
four TIMPs as well as MMP:TIMP ratios during term and preterm labor.
Methods: A case control study with 166 singleton pregnancies, divided into four groups: (1) women with preterm birth,
delivering before 34 weeks (PTB); (2) gestational age (GA) matched controls, not in preterm labor; (3) women at term in labor
and (4) at term not in labor. MMP and TIMP concentrations were measured using Luminex technology.
Results: MMP-9 and TIMP-4 concentrations were higher in women with PTB vs. GA matched controls (resp. p = 0.01 and
p,0.001). An increase in MMP-9:TIMP-1 and MMP-9:TIMP-2 ratio was observed in women with PTB compared to GA matched
controls (resp. p = 0.02 and p,0.001) as well as compared to women at term in labor (resp. p = 0.006 and p,0.001). Multiple
regression results with groups recoded as three key covariates showed significantly higher MMP-9 concentrations, higher
MMP-9:TIMP-1 and MMP-9:TIMP-2 ratios and lower TIMP-1 and -2 concentrations for preterm labor. Significantly higher
MMP-9 and TIMP-4 concentrations and MMP-9:TIMP-2 ratios were observed for labor.
Conclusions: Serum MMP-9:TIMP-1 and MMP-9:TIMP-2 balances are tilting in favor of gelatinolysis during preterm labor.
TIMP-1 and -2 concentrations were lower in preterm gestation, irrespective of labor, while TIMP-4 concentrations were
raised in labor. These observations suggest that aberrant serum expression of MMP:TIMP ratios and TIMPs reflect pregnancy
and labor status, providing a far less invasive method to determine enzymes essential in ECM remodeling during pregnancy
and parturition.
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Introduction
Matrix metalloproteinases (MMPs) are proteolytic, zinc-de-
pendent enzymes[1–6] capable of degrading extracellular matrix
(ECM) components, including collagen [1,4,5,7,8]. The human
MMP family currently consists of 26 members [1] and is classified
according to substrate specificity into collagenases, gelatinases,
stromelysines, matrilysins, membrane type-MMPs and other
MMPs [1,6,7,9]. More specifically, MMP-9, also known as
gelatinase B, plays a role in the remodeling of collagenous ECM
[1] and cleaves collagen type IV, the major basement membrane
component, collagen type V and elastin [1,2]. MMP-3 or
stromelysin-1 degrades a wide range of ECM proteins and
participates in proMMP activation [1,6]. Their activity is
regulated by tissue inhibitors of metalloproteinases (TIMPs) of
which four have been identified.[1–4,6,10]. Inhibition of MMP
activity occurs in a 1:1 stoichiometric relationship [1,7,8,11]. The
balance between collagenolysis and its inhibition is critical during
ECM remodeling [1,6]. An imbalanced MMP:TIMP ratio has
been involved in various medical conditions in humans including
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cancer, rheumatoid arthritis, osteoarthritis, endometriosis and
vascular diseases [1,7,8].
Human pregnancy is characterized by a steady remodeling of
the collagenous ECM in order to adapt fetal membranes and
cervix to uterine and fetal growth as gestation progresses [4,12].
MMPs play also a crucial role in birth-related events, including
cervical ripening and dilatation and membrane weakening and
rupture [2,4]. Some MMPs (e.g. MMP-1, MMP-2 and MMP-3)
are constitutively expressed during gestation, while the production
of others (e.g. MMP-9) are induced by active labor [2,3,13,14].
Aberrant ECM degradation by MMPs has been documented
during pregnancy complications including preterm birth. Preterm
birth (PTB), defined as a delivery before 37 completed weeks
gestation, is a multifactorial syndrome in which intrauterine
infection (IUI) is one of the most important mechanisms involved
[15,16]. IUI trigger MMP production via inflammatory mediators
[17]. Activation of the MMP cascade causes ECM degradation,
predisposing membrane rupture and cervix ripening [2,12,18].
A number of studies have shown that IUI[19–22], spontaneous
rupture of the membranes [11,21–27] and parturition[21–
24,26,28] either term or preterm are associated with elevated
MMP-9 concentrations in amniotic fluid, but few studies have
investigated the involvement of MMP-3 in labor and parturition.
Increased MMP-3 levels were found in amniotic fluid during term
as well as preterm parturition [13,29] and in cases of IUI [29,30].
A fully functional TIMP network has been demonstrated in fetal
membranes, decidua and placenta, irrespective of labor status[31–
33]. The majority of studies focused only on TIMP-1 and TIMP-
2. TIMP-1 concentrations in amniotic fluid were increased in the
presence of IUI [21,23] and in patients with rupture of the
membranes either term or preterm [11,23], but not in those with
spontaneous labor [11,24]. In contrast, TIMP-2 levels were
decreased in women with IUI, rupture of the membranes and
spontaneous labor [11,27,34]. Furthermore, it has been shown
that amniotic fluid levels of TIMP-1 decrease with advancing
gestational age [24,26] while those of TIMP-2 do increase [34].
We hypothesized that aberrant MMP expressions at local level
implicated in ECM degradation of the amniochorion and cervix,
are associated with aberrant changes in circulating MMPs,
resulting in imbalanced MMP:TIMP ratios and leading to preterm
labor. We therefore sought to determine the maternal serum
concentrations of MMP-3, MMP-9 and all four TIMPs as well as
the MMP:TIMP ratios during term and preterm labor.
Materials and Methods
Ethics Statement
The study was approved by the Ethical Committee of Ghent
University hospital (EC/2009/010). All participants provided oral
and written informed consent.
Study Design and Population
We performed a prospective cohort study (March 2009 to
December 2011) in which 768 pregnant women between 24 and
42 weeks’ gestation, presenting to the labor and delivery ward of
Ghent University hospital, a 1000-bed tertiary referral facility,
were enrolled in order to build a bank of biological samples and
clinical data and to explore putative associations between in-
flammatory markers of term and preterm labor. All subjects for
this study were selected from the prospective cohort, except
patients in group 2 (see below). A convenience sample of 166
singleton pregnancies was selected and divided into four groups
according to gestational age (GA) and labor status: Group 1 women
with preterm labor (PTL), allocated to the PTB group when
delivered before 34 weeks gestation (PTB) (n = 47). This group
included 32 patients with preterm premature rupture of the
membranes (PPROM) and 15 with PTL and intact membranes.
Group 2 consisted of women not in labor, attending the prenatal
clinic of Ghent University Hospital and matched for week of
gestation with the PTB group. All these women had an
uncomplicated pregnancy that proceeded to term delivery (GA
matched controls) (n = 47). Group 3 consisted of normal pregnant
women at term in labor (AT in labor) (n = 40). This group included
patients in labor with intact membranes (n = 20) and women with
rupture of the membranes (PROM) (n= 20). Group 4 consisted of
healthy pregnant women at term not in labor, undergoing
a primary Caesarean section (AT not in labor) (n = 32). Because of
logistic reasons, MMP-3 analyses were performed on a non-
selective sample of 116 singleton pregnancies, divided among the
subgroups as follows: 34 PTB, 34 GA matched controls, 27 AT in labor
and 21 AT not in labor. Inclusion criteria were age $18 years,
gestational age $24 weeks, absence of fetal (congenital) mal-
formations, absence of infectious disease (e.g. HIV, hepatitis B),
acute infection and Dutch speaking. Maternal demographic,
medical and obstetrical data were collected upon admission.
Definitions
PTL was defined as having regular uterine contractions (six to
twelve contractions in one hour) with cervical changes before 37
completed weeks of gestation. Cervical changes include cervical
effacement or dilatation, cervical shortening (,25 mm) and/or
funneling and were measured by vaginal examination or
transvaginal sonography. PPROM was defined as amniorrhexis
before the onset of PTL. A confirmatory test (crystallization test on
slide or rapid rupture of membranes (ROM) - test (Amnisure,
Boston, US)) was performed if PPROM was suspected on the basis
of fluid leakage or oligohydramnion. In case of a positive test, the
diagnosis of PPROM was considered. PTB was defined as PTL
and/or PPROM that led to a delivery before 34 weeks of
gestation. Gestational age was determined based on last menstrual
period, corrected by early ultrasound before 20 weeks gestation.
Sample Collection and Processing
Blood samples of laboring women (either term or preterm) were
collected by the attending midwife upon admission to the labor
and delivery ward. Women at term not in labor were sampled
prior to their Caesarean section. GA matched controls were enrolled
from the prenatal clinic. These pregnant women were screened at
20–22 weeks (structural ultrasound) to verify whether they fulfilled
the inclusion criteria. When they were eligible for participation,
the study was explained and they were matched for week of
gestation with a PTB case. Sampling was performed during
a subsequent prenatal consultation at the appropriate gestational
age.
Serum was obtained after coagulation of blood in the presence
of clot activator, followed by centrifugation for 10 minutes at
1000 g at room temperature and than frozen at minus 80uC until
analysis. Samples used for this analysis were never thawed
previously. MMP concentrations (MMP-3, -9 and -13) were
determined using a Human Matrix Metalloproteinases 3-Plex
Panel (Invitrogen, Inc. Carlsbad, CA). The 3-Plex was validated
for serum by performing spike and recovery and linearity-of-
dilution experiments. MMP-13 concentrations in maternal serum
were undetectable using this method in all samples. At a twofold
dilution of serum, concentrations were below the detection limit
and recovery fell outside the range 70–130%. Recovery and
linearity-of-dilution were within the acceptable range for MMP-3
(97–116%) and MMP-9 (74–114%). However, different serum
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dilutions were required to obtain fluorescence signals within the
linear range of detection (an 80-fold dilution for MMP-9 and a 2-
fold dilution for MMP-3). TIMP levels (TIMP-1, -2, -3 and -4)
were assessed using a Human TIMP Multiplex Kit according to
the manufacturers’ instructions (R&D systems, Minneapolis, MN).
MMP and TIMP levels were measured using Luminex technology
(Luminex 200, Luminex Corporation, Austin, TX).
Statistical Analysis
Univariate group differences were tested with Fisher’s Exact test
for categorical and Mann-Whitney U-test for continuous variables.
As multiple markers were considered as outcome variables, we
accounted for multiple testing by applying the Bonferroni
correction: where appropriate, adjusted p-values were obtained
by multiplying with the total number of markers and ratios and
used to evaluate significance.
The normality of continuous data was evaluated using the
Kolmogorov-Smirnov test and visual inspection of QQ-plots.
Since the distributions of MMPs and TIMPs were positively
skewed, their natural log transformed values were used so as to
have normally distributed outcome variables for multiple re-
gression analysis, which was performed on the full dataset. The
subgroups were translated into three variables: preterm (vs. at
term), labor (vs. not in labor) and rupture of membranes (ROM)
(vs. intact membranes).
Because these key covariates were the focus of our investigation,
they remained in the models regardless of their significance. To
adjust for possible confounding effects, the following covariates
were considered in the model selection procedure: maternal age,
education level, marital status, smoking, body mass index (BMI),
history of PTB, storage time and time delay between sampling and
processing (referred to as sample age). This set of covariates was
included in the initial model of the selection procedure for each
outcome. Model selection was carried out for each outcome
independently and occurred in two steps. First, a backward
selection of main terms was applied in which covariates were
sequentially removed in order of increasing significance until only
terms with p-value below 0.10 remained. In the second step, first
order interactions were considered between the covariates
remaining in the model. The forward selection of interaction
terms was performed with an inclusion criterion of p = 0.05. When
no further interactions met this criterion, the final model was
obtained for that outcome.
Unless noted otherwise, all statistical analyses and tests were
performed two-sided at the 5% significance level using SPSS
statistics 19 software (IBM, Chicago, Illinois).
Results
Demographic and Clinical Characteristics of the Study
Population
Maternal and clinical characteristics of the study population
(n = 166) are summarized in Table 1. No significant differences
were found regarding pre-pregnancy BMI, marital status, ethnic-
ity, conception, parity and history of PTB. Women with PTB had
a significantly lower education level than GA matched controls
(P = 0.003). There were significantly more smokers among women
with PTB as compared to women AT in labor (P = 0.007).
Significant differences were also found in maternal age (P= 0.03)
and the proportion of smokers (P = 0.04) between women AT not in
labor and women AT in labor. As these comparisons evaluated
different aspects of the study population and were not part of
a family of tests, no correction for multiple testing was applied.
Demographic and clinical characteristics were similar for the 116
singleton pregnancies included in the MMP-3 analysis (data not
shown).
Serum MMPs and TIMPs Concentrations and MMP:TIMP
Ratios
MMP-3, TIMP-1, TIMP-2 and TIMP-4 were detectable in all
serum samples, MMP-9 in 97.2% and TIMP-3 in only 26.7% of
samples. Serum MMP-9 concentrations of 4 samples (all patients
from the PTB group) were outside the linear range and omitted
from further analysis. TIMP-3 levels were below detection limits of
the assay in most samples (75.3%) and this parameter was
therefore omitted from further analyses. As mentioned previously,
MMP-13 could not be assessed in serum. Because we investigated
2 MMPs, 3 TIMPs and 6 MMP:TIMP ratios, we obtained
Bonferroni-adjusted p-values by multiplying p-values with a factor
11. In the text, we report the adjusted p-values. Serum MMP-3,
and -9, TIMP-1, -2 and -4 concentrations and their ratios are
summarized in Table 2.
Women with preterm birth vs. GA matched
controls. Median levels of MMP-9 and TIMP-4 were signifi-
cantly higher in women with PTB compared to GA matched
controls (respectively P= 0.001 and P,0.001). The same was true
for median MMP-9:TIMP-1 and MMP-9:TIMP-2 ratios (re-
spectively P,0.02 and P,0.001).
Women at term in labor vs. at term not in labor. No
significant differences in MMP-9, MMP-3, all TIMP concentra-
tions or any of the MMP:TIMP ratios were observed between
women AT in labor vs. AT not in labor.
Women with preterm birth vs. at term in labor. Median
TIMP-2 levels were significantly lower in women with PTB
compared to those AT in labor (P,0.001). A significant higher
MMP-9:TIMP-1 and MMP-9:TIMP-2 ratio was observed in
women with PTB (respectively P = 0.006 and P,0.001). Higher
MMP-9 and lower TIMP-1 concentrations were observed in
women with PTB, but these differences were marginally not
significant (respectively P= 0.07 and P= 0.09).
Women with PPROM vs. PTL and intact membranes. In
the PTB group, no significant differences were observed in MMP-
9, MMP-3 or any of the MMP:TIMP ratios between women with
PPROM compared to those with PTL and intact membranes (data not
shown).
Determinants of MMP-3, MMP-9, TIMPs and MMP:TIMP
Ratios
Multiple regression analysis was performed on the full dataset.
After model selection, no significant interaction effects between the
covariates were found for any outcome. Results of the final models
are shown in Table S1. Since the models used the natural log of
marker concentration as outcome variable, model coefficients
reflect differences on the ln(concentration) scale. To allow
interpretation on the original concentration scale, we also provide
exponentiated coefficients that reflect relative (percent wise)
instead of absolute changes. The R2 of our regression models
varied from 7 to 33%, indicating a large amount of variation in log
marker concentration (ratio) not explained by the covariates
included.
Preterm vs. at Term
Our regression results showed that, after adjusting for other
covariates, MMP-9 and all MMP-9:TIMP ratios were significantly
higher for preterm (vs. at term, P,0.001), whereas TIMP-1 and
TIMP-2 were significantly lower for preterm (P = 0.002 resp.
P,0.001). In particular, the average MMP-9 concentration as
MMP:TIMP Imbalance in Serum during Preterm Labor
PLOS ONE | www.plosone.org 4 November 2012 | Volume 7 | Issue 11 | e49042
well as all MMP-9:TIMP ratios were more than double preterm
while the average TIMP-1 and TIMP-2 concentrations were lower
(respectively 11% and 22%). Regression results show no significant
association between preterm and MMP-3 or any of the MMP-
3:TIMP ratios.
Labor vs. No Labor
The regression results showed that, after adjusting for other
covariates, MMP-9 concentrations and MMP-9:TIMP-2 ratios
were significantly higher for labor (vs. no labor, resp. P= 0.03 and
P=0.04), the same was true for TIMP-4 concentrations
(P,0.001). In particular, the average MMP-9 concentration and
MMP-9:TIMP-2 ratio were 51% resp. 49% higher in labor.
Additionally, the average TIMP-4 concentration was 33% higher
in labor. MMP-9:TIMP-1 ratios tended to be higher (632%) in
labor, although the adjusted p-value was not significant. Regression
results show no significant association between labor and MMP-3
or any of the MMP-3:TIMP ratios.
Rupture of the Membranes vs. Intact Membranes
The regression results show no significant association between
rupture of the membranes and MMP, TIMP concentrations or any of
their ratios.
Other Covariates
Other important covariates withheld in the regression models
are history of PTB, storage time (i.e. window between storage and
analysis) and BMI.
Our regression results showed that MMP-9 concentrations and
all MMP-9:TIMP ratios tended to be lower for women with
a history of PTB, but not significantly. For example, the average
MMP-9 concentration was 39% lower in women with a history of
PTB. Furthermore, regression results demonstrated that storage time
was significantly associated with MMP-9 concentrations and all
MMP-9:TIMPs ratios (all P,0.05). With other variables held
constant, MMP-9 concentrations multiplied with a factor 1.010
(i.e. increased with 1%) for every additional week of storage.
Finally, MMP-3 concentrations and MMP-3:TIMP-1 and MMP-
3:TIMP-4 ratios decreased with increasing body mass index (all
P,0.10).
Discussion
The role of MMPs and to a lesser extent of TIMPs has been
widely investigated in human term and preterm parturition over
the past decades. The novelty of our study is the determination of
MMP-3, MMP-9 and all four TIMPs in maternal serum. A
number of studies have explored MMP-9 in amniotic fluid[11,19–
24,26,35,36]. This requires invasive procedures, while blood
samples can be easily obtained during pregnancy.
In line with previous observations in maternal plasma [37] and
amniotic fluid [22,24], we found that MMP-9 concentrations were
elevated in maternal serum during preterm labor. In contrast, we
observed no significant increase in MMP-9 levels during term
parturition. Furthermore, our results showed that labor was not
associated with a change in serum MMP-3 concentration. To our
knowledge, no previous study measured serum MMP-3 during
labor, although Park et al [29] reported that MMP-3 levels were
elevated in amniotic fluid from women with spontaneous labor at
term and preterm.
TIMPs are endogenous specific inhibitors that have been shown
to regulate the proteolytic activity of MMPs in normal and
pathological processes. A fully functional TIMP network has been
demonstrated in human fetal membranes [32,33], in placenta and
decidua [33], in the extra-embryonic coelomic fluid [38] and in
amniotic fluid during the second trimester [38]. The four
inhibitors were present in maternal serum, but TIMP-3 levels
could not be quantified in the majority of the samples.
Table 2. Comparison of MMP-3, MMP-9, TIMPs levels and MMP:TIMPs ratios in maternal serum among groups.
Group 1
PTB (n =47)
Group 2
GA matched controls
(n =47)
Group 3
AT in labor
(n =40)
Group 4
AT not in labor
(n =32)
Group 1 vs.
2 P-value $
Group 3 vs.
4 P-value$
Group 1 vs.
3 P-value$
MMP-9 1125.1 [694.1–1977.4] 639.5 [513.8–924.5] 828.7 [420.7–1259.8] 554.6 [377.5–711.3] ,0.001 (0.001) 0.06 (NS) 0.006 (0.07)
TIMP-1 132.04 [118.25–152.27] 125.65 [111.07–139.21] 149.49 [133.01–
185.46]
137.98 [125.18–
149.44]
0.08 (NS) 0.02 (NS) 0.008 (0.09)
TIMP-2 121.76 [107.62–132.19] 121.26 [109.35–135.82] 156.12 [139.67–
190.19]
137.71 [124.57–
164.27]
0.68 (NS) 0.03 (NS) ,0.001
(,0.001)
TIMP-4 1.46 [1.09–1.96] 1.04 [0.83–1.26] 1.24 [1.12–1.46] 1.08 [0.81–1.35] ,0.001
(,0.001)
0.01 (NS) 0.08 (NS)
MMP-9:TIMP-1 ratio 8.21 [4.82–13.88] 5.26 [3.89–7.09] 4.85 [2.86–8.98] 3.94 [3.07–5.33] 0.002 (0.02) 0.35 (NS) ,0.001 (0.006)
MMP-9:TIMP-2 ratio 9.68 [6.06–14.34] 5.23 [3.95–7.35] 4.61 [2.80–6.75] 3.69 [2.92–5.45] ,0.001
(,0.001)
0.26 (NS) ,0.001
(,0.001)
MMP-9:TIMP-4 ratio 847.3 [386.8–1463.3] 657.4 [434.0–995.9] 578.0 [342.7–980.3] 567.7 [337.6–765.7] 0.29 (NS) 0.57 (NS) 0.13 (NS)
PTB (n = 34) GA matched controls
(n = 34)
AT in labor (n = 27) AT not in labor
(n = 21)
P-value$ P-value$ P-value$
MMP-3 9.10 [5.83–15.53] 8.78 [4.68–14.97] 9.55 [3.96–15.83] 7.14 [4.76–13.46] 0.55 (NS) 0.76 (NS) 0.52 (NS)
MMP-3:TIMP-1 ratio 0.065 [0.046–0.111] 0.065 [0.032–0.136] 0.062 [0.033–0.108] 0.057 [0.035–0.093] 0.60 (NS) 0.88 (NS) 0.25 (NS)
MMP-3:TIMP-2 ratio 0.073 [0.058–0.118] 0.074 [0.041–0.111] 0.048 [0.031–0.103] 0.045 [0.030–0.102] 0.47 (NS) 0.99 (NS) 0.03 (NS)
MMP-3:TIMP-4 ratio 6.13 [3.86–12.40] 7.95 [4.84–13.37] 8.45 [3.94–11.37] 7.36 [4.06–11.37] 0.44 (NS) 0.96 (NS) 0.74 (NS)
Results are expressed as median (interquartile range) (ng/ml), group differences were evaluated with the Mann-Whitney U-test.
PTB, preterm birth; PT, preterm; AT, at term; NS, not significant.
$Unadjusted P values and Bonferroni-adjusted P values (adjusted for 11 tests) between brackets.
doi:10.1371/journal.pone.0049042.t002
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Multiple regression analysis showed that TIMP-1 and TIMP-2
levels were lower in preterm gestations compared to those at term,
irrespective of labor status. This is in agreement with Clark et al
[39], who demonstrated that TIMP-1 is suppressed during
pregnancy with increasing serum levels from 37 weeks onwards,
back to pre-pregnant levels. The similar observation was made in
amniotic fluid for TIMP-2 showing an increase in concentration
with advancing gestational age [34]. By contrast, amniotic fluid
levels of TIMP-1 have been shown to decrease with advancing
gestation [24,26].
TIMP-4 is the most recently identified member of the TIMP
family and differs from the other TIMPs in its restricted expression
pattern and its structure [40]. Recent reports showed that TIMP-4
is also disregulated during cancer invasion and progression of
several organs (for instance in reproductive organs) which
highlights its potential role as a biomarker or therapeutic target
of disease [40]. Previous research focused on TIMP-4 expression
in intrauterine compartments during early and term pregnancy
and term parturition. Fortunato et al [32] showed a sparse and
inconsistent TIMP-4 expression and low mRNA levels of TIMP-4
in the fetal membranes from laboring and non-laboring women.
Furthermore, TIMP-4 was present predominantly in the extra-
embryonic coelomic fluid, with low amounts in the amniotic fluid
of the first trimester, but significantly increasing with gestation
[38]. To the best of our knowledge, there is no information on
TIMP-4 in women with preterm labor. Our results showed
a significant increase in serum TIMP-4 concentrations during
labor (either term or preterm).
Imbalances in the MMP:TIMP ratios may underlie the
pathogenesis of various diseases [41,42] and have been associated
with progression [43], remission [44] and severity [45] of disease.
Importantly, case-control group comparison showed higher
MMP-9:TIMP-1 and MMP-9:TIMP-2 ratios in women with
preterm labor. These ratio shifts agreed with the higher MMP-9
and lower TIMP-1 and TIMP-2 concentrations in preterm labor.
Multiple regression analyses showed a strong association with
preterm status, as MMP-9:TIMP-1 and MMP-9:TIMP-2 ratios
were markedly significant higher for the key covariate preterm,
while for the key covariate labor only the MMP-9:TIMP-2 ratio
was significantly higher. Only few studies have investigated
MMP:TIMP ratios during preterm labor. One previous study of
Fortunato et al [11] found that the molar ratio between MMP-2
and TIMP-2, but not TIMP-1 was increased in amniotic fluid
during PPROM.
None of the MMPs or TIMPs concentrations and MMP:TIMP
ratios differed significantly between women with PPROM and
those with PTL and intact membranes. This finding is consistent
with Romero et al [25] who found higher MMP-9 concentrations
in the fetal compartments, but not in maternal plasma [25]. These
observations suggest that cytokine changes during pregnancy are
not always reflected in the maternal circulation which is in line
with data from animal models indicating that that alterations in
cytokine profiles are strictly compartmentalized and independently
regulated [46]. Recently, Brou et al [47] evaluated thirty-six
biomarkers in maternal, fetal and intra-amniotic compartment of
women with preterm labor and demonstrated that the biomarkers
of the PTB pathway differ between different compartments.
It has been shown that pre-analytical variability arising from
sampling and storage procedures affect assayed concentration of
biological markers [48,49]. The impact of storage time and sample
age on MMP and TIMP concentrations was considered in the
multiple regression analysis. Our regression results showed that
storage time was positively correlated with serum MMP-9
concentration after adjusting for other covariates. Studies in-
vestigating MMP-9 stability during long-term storage at 280uC
show conflicting results [50,51]. The reason for these discrepant
results is not clear. In our study, we found no interactions between
storage time and other covariates in the model, indicating no
differences in storage time between groups.
Some limitations of this study deserve consideration. First, the
relatively small sample size of this study. More women with
PPROM and PTL and intact membranes might be necessary to
determine differences in MMPs and TIMPs concentrations.
Therefore, large studies are required to confirm our results. Since
we conducted a case control study and MMP and TIMP
concentrations were measured only once upon admission, we
were unable to demonstrate the exact timing of the ratio shift
between MMP and TIMP. It has been shown that MMPs are
temporally regulated to perform specific functions during preg-
nancy [8]. For example, MMP-9 is selectively expressed in the
decidua and fetal membranes with the onset of labor, but barely
detectable before labor [4]. Furthermore, it would be interesting to
evaluate whether MMP:TIMP ratios differ between patients with
preterm labor who delivered preterm and those delivering at term.
A preliminary evaluation showed no significant differences, but the
number of patients with preterm labor and term delivery was
rather low (n= 10). Finally, we only evaluated immunoreactive
forms of MMP-3 and -9 with a MMP 3–plex detecting all
circulating MMPs (including pro, active and TIMP bound forms).
An alternative would be to evaluate the enzymatic activity of
MMPs, because the mere presence of MMP does not necessarily
establish their catalytic capacity [8]. Fortunato et al [11]
demonstrated that only a small amount of total amniotic fluid
MMP-9 and -2 were active. However, it has been shown that the
immunoreactivity of MMP-9 in amniotic fluid correlates well with
its enzymatic activity [23].
In conclusion, this study showed that MMP-9:TIMP-1 and
MMP-9:TIMP-2 balances in maternal serum are tilting in favor of
gelatinolysis in women with preterm labor. All four TIMPs were
expressed in maternal serum. While TIMP-1 and -2 concentra-
tions were lower during gestation, irrespective of labor, TIMP-4
levels were elevated during labor (either at term or preterm). The
observations in the present study indicate that circulating MMPs
and TIMPs may also play a role in the pathogenesis of preterm
labor at systemic level or at least reflect pregnancy and labor
status. Our findings provide the possibility to develop a far less
invasive approach (compared to amniocentesis) for measurement
of enzymes essential for ECM remodeling during pregnancy and
parturition. However, a great deal still remains to be learned about
MMPs and in particular TIMPs during various stages of normal
pregnancy and labor as well as in pathological conditions such as
preterm labor.
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